Eye on the Ball: Medicine regulation – not IP enforcement – can best deliver quality medicine
Poor-quality medicines pose a serious threat to patients and public health in developing countries. The World Health Organisation estimates nearly one-third of all countries lack adequate drug-regulatory capacity to monitor medicines safety.
Under the guise of addressing this problem, some rich countries are pushing for new intellectual-property rules and a reliance on police action to keep substandard medicines out of reach. Such an approach will not ensure consistent medicine quality. Worse, it threatens to undermine access to legitimate, affordable generic medicines.
Donors and developing countries must prioritize building competent regulatory authorities – not expand intellectual-property enforcement – so that patients can be assured that the medicines they take are safe and effective.
How to cite this resource
Citation styles vary so we recommend you check what is appropriate for your context. You may choose to cite Oxfam resources as follows:
Author(s)/Editor(s). (Year of publication). Title and sub-title. Place of publication: name of publisher. DOI (where available). URL
Our FAQs page has some examples of this approach.